You are here

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

Authors

  • Javier Martin-Broto Medical Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain PubMed articlesGoogle scholar articles
  • Nadia Hindi Medical Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain PubMed articlesGoogle scholar articles
  • Giovanni Grignani Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS - Str. Prov.le 142, km. 3,95 - Candiolo (TO) 10060, Candiolo, Italy PubMed articlesGoogle scholar articles
  • Javier Martinez-Trufero Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain PubMed articlesGoogle scholar articles
  • Andres Redondo Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain PubMed articlesGoogle scholar articles
  • Claudia Valverde Department of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Silvia Stacchiotti Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Via Venezian 1, Milan, Italy PubMed articlesGoogle scholar articles
  • Antonio Lopez-Pousa Medical Oncology Department, Sant Pau Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Lorenzo D'Ambrosio Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS - Str. Prov.le 142, km. 3,95 - Candiolo (TO) 10060, Candiolo, Italy PubMed articlesGoogle scholar articles
  • Antonio Gutierrez Medical Hematology Department, University Hospital Son Espases, Mallorca, Spain PubMed articlesGoogle scholar articles
  • Herminia Perez-Vega Radiology Department, University Hospital Virgen del Rocio, Sevilla, Spain PubMed articlesGoogle scholar articles
  • Victor Encinas-Tobajas Radiology Department, University Hospital Virgen del Rocio, Sevilla, Spain PubMed articlesGoogle scholar articles
  • Enrique de Alava Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital /CSIC/University of Sevilla/CIBERONC, Sevilla, Spain Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41009, Sevilla, Spain PubMed articlesGoogle scholar articles
  • Paola Collini Soft Tissue and Bone Pathology, Histopathology and Pediatric Pathology Unit, Diagnostic Pathology and Laboratory Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale Tumori, Milan, Italy PubMed articlesGoogle scholar articles
  • Maria Peña-Chilet Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, Sevilla, Spain Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, Sevilla, Spain PubMed articlesGoogle scholar articles
  • Joaquin Dopazo Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, Sevilla, Spain Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, Sevilla, Spain INB-ELIXIR-es, FPS, Hospital Virgen del Rocío, Sevilla, Spain PubMed articlesGoogle scholar articles
  • Irene Carrasco-Garcia Medical Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain PubMed articlesGoogle scholar articles
  • Maria Lopez-Alvarez Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain PubMed articlesGoogle scholar articles
  • David S Moura Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain PubMed articlesGoogle scholar articles
  • Jose A Lopez-Martin Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Javier Martin-Broto; jmartin{at}mustbesevilla.org
View Full Text

Citation

Martin-Broto J, Hindi N, Grignani G, et al
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
Journal for ImmunoTherapy of Cancer 2020;8:e001561. doi: 10.1136/jitc-2020-001561

Publication history

  • Accepted October 19, 2020
  • First published November 17, 2020.
Online issue publication 
November 17, 2020

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.